MSK, NYGC Collaborative Study Pinpoints New Cause of Resistance to EGFR-Targeting Drugs


A collaborative study between scientists at Memorial Sloan Kettering Cancer Center and the New York Genome Center has identified one way that lung cancer cells outsmart a common targeted drug therapy. The results, reported June 6, 2018 in the Proceedings of the National Academy of Sciences, pave the way for improved treatments.